

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

UNAUDITED

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

CONTENTS

	Page
Reference and administrative details of the company, its Trustees and advisers	1
Trustees' report	2 - 9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13 - 30

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS
FOR THE YEAR ENDED 31 MARCH 2025**

Trustees

Nicholas Jones (resigned 18 January 2026)
Ailsa Arthur
Sarah Chikhani
Rachel Thomas
Dr Florence Osborne, Chair
Dr Charlotte Dawson
Kempton Rees
Karolina Stepień (appointed 18 January 2026)

Company registered number

06981121

Charity registered number

1132271

Registered office

Black Country House, Rounds Green Road, Oldbury, West Midlands, B69 2DG

Independent examiner

Crowe U.K. LLP, Black Country House, Rounds Green Road, Oldbury, West Midlands, B69 2DG

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT
FOR THE YEAR ENDED 31 MARCH 2025

The Trustees present their annual report together with the financial statements of the company for the year 1 April 2024 to 31 March 2025. The Annual report serves the purposes of both a Trustees' report and a directors' report under company law. The Trustees confirm that the Annual report and financial statements of the charitable company comply with the current statutory requirements, the requirements of the charitable company's governing document and the provisions of the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January 2019).

Since the company qualifies as small under section 382 of the Companies Act 2006, the Strategic report required of medium and large companies under the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013 has been omitted.

Objectives and activities

a. Policies and objectives

The objects of the Association for Glycogen Storage Disease (UK) as recorded in its Memorandum of Association, is "The relief of sickness, particularly of persons suffering from any form of Glycogen Storage Disease". The Association works to protect and promote the best interests of persons affected by GSD.

Public Benefit

The Trustees confirm that they have complied with the duty in section 17 of the Charities Act 2011 to have due regard to public benefit guidance published by the Commission in determining the activities undertaken by the Charity.

The Charity Commission in its "Charities and Public Benefit" Guidance states that there are two key principles to be met in order to show that an organisation's aims are for the public benefit: firstly, there must be an identifiable benefit and secondly, that benefit must be to the public or a section of the public. The Trustees are satisfied that the aims and objectives of the charity, and the activities reported on below to achieve those aims, meet these principles.

b. Strategies for achieving objectives

The Association acts as a vehicle of communication on GSD related matters by publishing and distributing relevant material. It contributes to the advancement of treatments and cures through sponsorship of research, studies and trials. It acts as a focus for educational, scientific and charitable activities related to GSD. The Association liaises with other GSD Associations around the world. Please see Review of activities section for details of our current strategy.

c. Activities undertaken to achieve objectives

The main activities are the support of patients and families; the organising of conferences and workshops to promote understanding of the disease; the publication of a newsletter; the provision of information about Glycogen Storage Disease through publications and a web site; and the provision of grants to research bodies and individuals. These activities support the objects by assisting patients; by encouraging and supporting research into the disease and by educating the medical profession and concerned members of the general public about the disease.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Objectives and activities (continued)

d. Grant-making policies

The Association receives applications for grants to support research projects in relation to Glycogen Storage Disease. Applications for grants are considered by the Board of Trustees and by members of the Association's Medical Advisory Board. Whenever possible the Association co-sponsor together with other charities or foundations. The Association also occasionally makes small grants to individual applicants for personal expenses associated with their treatment, care and well-being.

Achievements and performance

a. Review of activities

During the 2024-25 financial year we continued to work towards the goals of our current strategic plan. These are drawn from priorities identified by community members and comprise:

Theme: Support across the community.

Goal: Everyone affected will be connected to an active and supportive GSD community.

Theme: Help with living well.

Goal: People with any GSD will be offered the information and activities they need to live well with the condition.

Theme: Better treatments and service access.

Goal: The community will experience improved management, treatment and service access.

Theme: Strong and effective organisation.

Goal: AGSD-UK will grow sustainably, with robust governance, to increase our impact.

Support across the community

Over the course of the year the intensive advocacy provided by our care and benefits advisors enabled community members to access much needed services such as home adaptations and equipment grants, education and health care packages, transport, enhanced social care and a range of welfare benefits. Individuals and families also received valued support with issues like dealing with diagnosis, parenting and employment rights. Their feedback included:

- "AGSD UK truly is a breath of fresh air for people facing the challenges of rare conditions. Your charity provides more than just advice; you offer a lifeline of empathy, understanding, and non-judgmental support to those who need it most."
- "I would like to express my heartfelt gratitude to AGSD UK. I have Pompe disease, and at times, it can make you feel isolated. Coping with the constant changes to your health and mobility, as well as the day-to-day challenges, can be incredibly tough. AGSD UK has been an unwavering source of support for me."
- "[AGSD-UK advisors] have been instrumental in guiding me through the complexities of benefit programs, including DLA and carer's allowance, and have also provided invaluable assistance in assessing my overall benefit entitlements. Their support extended beyond paperwork, as they even helped me access food vouchers during times of real hardship."

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance (continued)

Our local get-togethers connecting people with others affected also received a very positive response from those attending:

- “We had an amazing time and thoroughly enjoyed ourselves. It was such a valuable experience to meet other families facing similar health challenges, which made us feel much less isolated.”
- Living with such a rare condition can be tough, especially when people don’t always understand what we go through, so connecting with others who do was incredibly comforting.”
- “...it was great to connect with other parents of children with GSD and share our experiences, challenges and daily worries.”

Help with living well

Two McArdle’s walking courses for under 21s and for adults took place in Wales during July and August 2024 and, as usual, were greatly appreciated by those taking part:

- “Just wanted to thank you again for organising the walking course and encouraging me to come on it. I had a great time and feel like I learnt a lot.”
- “These weekends/weeks are life-changing and life-affirming. From the bottom of my heart, thank you all for an amazing week.”
- “The twins got to be with other teens, young people and older McArdleites. They got to climb mountains they (and we) would never have attempted and do physical things that were bold and audacious.”
- “I enjoyed the amazing walks that we went on and the cooking. I really liked the activities we did after the walks, like bracelet making, playing games and paddling in the river!”

Our monthly Living well socials continue to be extremely well received and a thriving WhatsApp group has been developed alongside the meetings to facilitate mutual support:

“Wonderful place to be. Love how positive it is. Thank you... for this safe space”

Our regular Glisten magazine packed with information about living with GSDs was widely distributed and further information sheets produced. Website views for the financial year totalled 38,020.

Our Main Event for the community staged during the 2024-5 financial year again received outstanding feedback. The evaluation forms completed showed that:

- 100% said the event enabled them to connect with others with similar experiences
- 100% said the event gave them the chance to gain tips about living with GSDs
- 100% said the event allowed them to become better informed about research and developments in the field of GSDs

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance (continued)

- 100% said the event provided the opportunity to get information about support and services that are available
- 100% said they had fun and enjoyed themselves

The following is just a small selection of the comments received:

- "It was superb. Team was great-very helpful. Would like to attend again."
- "Good mix of scientific updates, patient support and fun activities."
- "Loved the music therapy on Sunday a.m."
- "The whole AGSD-UK team are wonderful –I thoroughly enjoyed the meeting."
- "We were very impressed with the organisation and the agenda."
- "It was a very valuable experience coming to this event with my family as not only did we meet people who are dealing with the same thing as us but also with professionals who mirror the work they do with our centre."
- "Heartfelt thanks for an incredibly well-organised and impactful conference...The programme itself was so well curated, delivering both depth and relevance that kept us all engaged throughout the weekend..."
- "Your hard work, attention to detail and dedication made the event run smoothly and successfully. The sessions were insightful. We truly appreciated it."
- "Thank you so much for looking after us. Your care and attention meant a lot. We're truly grateful for everything you do to keep us comfortable and supported. Thank you."
- "This was our first time at the conference. Everyone was really helpful and supportive. Thank you so much."
- "Excellent weekend -informative and fun. Thank you."

Better treatments and service access

Throughout the year we continued to support and promote multiple opportunities for people affected by GSDs to shape and take part in research and trials to enable the development of better treatments. We also worked with industry, health professionals and other charity partners to influence service quality.

Work began on the two Loughborough University PhD research programmes relating to diet, exercise and mental health and digital biomarkers in hepatic GSDs that we are joint-funding with the generous support of the Mosawi Foundation.

We took part in two further international online meetings organised by the Adult Polyglucosan Body Disease Research Foundation, focused on bringing the APBD and GSD IV communities together to develop a joint action and communications plan. AGSD-UK was also represented at an Aspire biosciences speed-dating event, this time with a view to exploring potential partnerships for new treatments for hepatic GSDs.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Achievements and performance (continued)

Strong and effective organisation

We continued to benchmark the organisation against established voluntary sector standards, strengthening our processes and policies to ensure these are robust and in line with best practice. This included reviewing ways to ensure our board remains fully inclusive and open to new members to bring a range of skills, ideas and perspectives to our governance and cause. We remain extremely grateful to all those who contribute their time, energy and expertise to help enable AGSD-UK to respond to the needs of those affected by this challenging condition.

Financial review

a. Going concern

The trustees have reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting is appropriate in preparing the annual financial statements.

b. Reserves policy

The Association holds some funds that are restricted in expenditure in support of particular GSD Types and other projects (see note 17). The general reserves are used to support the on going activities of the Association. The unrestricted general reserve now stands at £35,987 which is a decrease from the previous year (£43,596). The trustees' future focus will be on increasing income while tightly managing costs. The total restricted funds is now £53,836 (2024: £84,486).

In line with most small charities AGSD UK aims to spend most of the funds raised during any given financial year for the benefit of its members and the public and not to build up a large general reserve. The trustees have agreed to adopt a reserve policy that seeks to carry forward an unrestricted general reserve figure that is no greater than 25% of total in year expenditure.

The funds freely available for use by the charity at the year end at the discretion of the Trustees, amount to the unrestricted reserves less the unrestricted tangible fixed assets of £594. Our free reserves at 31 March 2025 are therefore £35,393 (2024: £42,798).

c. Investment policy and performance

The Association holds its cash reserves in bank deposit accounts thus eliminating investment risk and minimising any other risk to the reserves. No long term deposits are made as it is anticipated that the reserves will continue to be called upon to support a high level of activity.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Structure, governance and management

a. Constitution

The company is registered as a charitable company limited by guarantee and was set up under a Memorandum of Association. The company is constituted under a Memorandum of Association dated 05/08/2009 and is a registered charity number 1132271. The principal object of the company is to provide "The relief of sickness, particularly of persons suffering from any form of Glycogen Storage Disease".

b. Methods of appointment or election of Trustees

The management of the company is the responsibility of the Trustees who are elected and/or co opted under the terms of the Articles of Association. Any full member of the Association may be nominated to stand for election to the Board of Trustees. The Trustees have the power to co-opt new Trustees who are then required to stand for election at the next AGM.

c. Organisational structure and decision-making policies

The Association is a membership based association, with full membership being open to anyone affected by Glycogen Storage Disease and the close family of such persons. The members elect the Board of Trustees. The Board of Trustees elects its own officers. The Board of Trustees are responsible for ensuring that the charity complies with all relevant regulations and files its annual report and accounts with the Charity Commission and Companies House.

The Board of Trustees delivers the strategy through the Chief Executive and any other staff plus a range of volunteers.

The Board appoint a volunteer Co-ordinator for each of the GSD types, wherever possible. The defined role is wide ranging and is not necessarily entirely relevant or practical for each GSD Type, where the numbers affected and their needs vary enormously. The Co-ordinators meet as a group three times a year for peer support and development in their role.

d. Pay policy for key management personnel

The company currently has one part-time permanent member of staff – the Chief Executive, with four part-time freelance team members.

The remuneration for key management posts was benchmarked at or below market rate prior to appointment and is reviewed by Trustees annually.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Structure, governance and management (continued)

e. Financial risk management

The Trustees have assessed the major risks to which the company is exposed, in particular those related to the operations and finances of the company, and are satisfied that systems and procedures are in place to mitigate exposure to the major risks.

f. Risk Management

The Trustees have assessed the major risks to which the company is exposed. The current major risks to the charity are primarily in the areas of operation and finance as follows:

Income generation
Cost control
Banking control
I.T. stability and security
Adoption of and adherence to policies and procedures
Loss of key personnel

The Trustees are satisfied that systems, procedures and plans are in place to mitigate exposure to major risks.

Plans for future periods

The period April 2025-26 is the last of our current strategy and we remain focused on delivering our stated goals. This involves further expansion of our support offer and facilitation of peer support, with a wider range of groups to meet the needs of under-served sections of the community, including children and young people.

We will take forward updating of our website, ensuring this contains the current evidence-based information people need to help them live well and is attractive, engaging and easy to navigate.

Our ongoing research support will ensure studies and developments in treatment and management are shaped by the needs of the community.

We will also complete our work to benchmark the organisation against best practice standards for the sector, as part of our quality improvement cycle.

In addition, we will take forward a community listening exercise to inform the key goals for our next three year strategy.

To deliver our plans we will continue to support fundraising efforts within the community, while seeking the help of grant making trusts aligned with our goals and working closely with our valued industry partners.

We would like to express our appreciation to all those individuals and organisations who contribute to our work and our special thanks go to; Amicus, Beam, Community Fund, D'Oyly Carte Charitable Trust, Mosawi Foundation, Sanofi, Ultragenyx and Vitaflor for their commitment to improving life for people affected by GSD.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

TRUSTEES' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2025

Statement of Trustees' responsibilities

The Trustees (who are also the directors of the company for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial . Under company law, the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees on 29/01/2026
and signed on their behalf by:

Florence Osborne

Florence Osborne (Jan 29, 2026 10:18:40 GMT)

Dr Florence Osborne
Chair

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**INDEPENDENT EXAMINER'S REPORT
FOR THE YEAR ENDED 31 MARCH 2025**

Independent Examiner's Report to the Trustees of Association for Glycogen Storage Disease (UK) Limited ('the company')

I report to the charity Trustees on my examination of the accounts of the company for the year ended 31 March 2025.

Responsibilities and Basis of Report

As the Trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the company's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the company's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the company's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the company's Trustees as a body, for my work or for this report.

Signed:



Dated: 29 January 2026

Helen Blundell

LLB FCA FCIE DChA

Crowe U.K. LLP

Chartered Accountants
Black Country House
Rounds Green Road
Oldbury
West Midlands
B69 2DG

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2025**

	Note	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Income from:					
Donations and legacies	4	89,850	60,009	149,859	217,395
Charitable activities	5	-	830	830	875
Other trading activities	6	5,986	16,042	22,028	21,738
Investments	7	-	1,235	1,235	1,120
Other income	8	-	-	-	1,149
Total income		95,836	78,116	173,952	242,277
Expenditure on:					
Charitable activities		145,124	67,087	212,211	197,548
Total expenditure		145,124	67,087	212,211	197,548
Net (expenditure)/income		(49,288)	11,029	(38,259)	44,729
Transfers between funds	18	18,638	(18,638)	-	-
Net movement in funds		(30,650)	(7,609)	(38,259)	44,729
Reconciliation of funds:					
Total funds brought forward		84,486	43,596	128,082	83,353
Total funds carried forward		53,836	35,987	89,823	128,082

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 13 to 30 form part of these financial statements.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)
REGISTERED NUMBER: 06981121

BALANCE SHEET
AS AT 31 MARCH 2025

	Note	2025 £	2024 £
Fixed assets			
Tangible assets	15	594	798
		<u>594</u>	<u>798</u>
Current assets			
Debtors	16	6,149	3,478
Cash at bank and in hand		93,253	130,666
		<u>99,402</u>	<u>134,144</u>
Current liabilities			
Creditors: amounts falling due within one year		(10,173)	(6,860)
	17	<u></u>	<u></u>
Total net assets		<u><u>89,823</u></u>	<u><u>128,082</u></u>
Charity funds			
Restricted funds	18	53,836	84,486
Unrestricted funds	18	35,987	43,596
Total funds		<u><u>89,823</u></u>	<u><u>128,082</u></u>

The company was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on 29/01/2026
and signed on their behalf by:

Florence Osborne
Florence Osborne (Jan 29, 2026 10:18:40 GMT)

Dr Florence Osborne
Chair

The notes on pages 13 to 30 form part of these financial statements.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025

1. General information

1.1 Company Status

The Association for Glycogen Storage Disease (UK) Limited is a company limited by guarantee in England, whose registered office is Black Country House, Rounds Green Road, Oldbury, West Midlands, B29 2DG. The company's registered number is 06981121. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Association for Glycogen Storage Disease (UK) Limited is a private company limited by guarantee and meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

2.2 Going concern

The trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. They continue to believe the going concern basis of accounting appropriate in preparing the annual financial statements.

2.3 Income

All income is recognised once the company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.4 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

2. Accounting policies (continued)

2.4 Expenditure (continued)

Expenditure on charitable activities is incurred on directly undertaking the activities which further the company's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Support costs are those costs incurred directly in support of expenditure on the objects of the company. Governance costs are those incurred in connection with administration of the company and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds.

Charitable activities and Governance costs are costs incurred in the company's educational operations, including support costs and costs relating to the governance of the company apportioned to charitable activities.

2.5 Cash flow

The company has taken advantage of the exemption in Financial Reporting Standard No.1 from the requirement to produce a cash flow statement on the grounds that it is a small charitable company.

2.6 Intangible assets and amortisation

Intangible assets costing £500 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Intangible assets are initially recognised at cost. After recognition, under the revaluation model, intangible assets shall be carried at a revalued amount, being their fair value at the date of revaluation less any subsequent accumulated amortisation and subsequent impairment losses - provided that the fair value can be determined by reference to an active market.

Revaluations are made with sufficient regularity to ensure that the carrying amount does not differ materially from that which would be determined using fair value at the end of the reporting period.

Amortisation is provided on intangible assets at rates calculated to write off the cost of each asset on a straight-line basis over its expected useful life.

Amortisation is provided on the following basis:

Website development	- 20 % straight line
---------------------	----------------------

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

2. Accounting policies (continued)

2.7 Tangible fixed assets and depreciation

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities incorporating income and expenditure account.

Tangible fixed assets are initially recognised at cost net of accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Office equipment	- 25% reducing balance
------------------	------------------------

2.8 Financial instruments

Debtors

Short term debtors are measured at transaction price, less any impairment.

Creditors

Short term trade creditors are measured at transaction price.

Cash

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours.

There are no complex financial instruments.

2.9 Pensions

The pension costs charges in the financial statements comprise contributions payable by the Charity during the year for a defined contribution personal pension plan for staff. The Charity contributes 3% of eligible pay for those employees enrolled in the plan.

2.10 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

2. Accounting policies (continued)

2.11 Role of Volunteers

The charity relies on the efforts of its volunteers. The value of these volunteers is not incorporated within the accounts.

3. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

Critical areas of judgment:

- (i) Donations of consulting by Andrew Wakelin
- (ii) Donations of conference guest speakers
- (iii) Donations of services including printing, graphic design, meeting rooms and consultant attendance of events

In accordance with the Charities SORP FRS 102, the charity has valued the benefit it receives from donations in kind of £55,505 (2024: £52,271). This is based on the open market value of benefits received.

4. Income from donations and legacies

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Donations	-	6,478	6,478	21,556
Legacies	-	-	-	5,000
Grants	67,290	18,000	85,290	134,550
Donations in kind	22,560	32,945	55,505	52,271
Gift aid	-	2,586	2,586	4,018
Total 2025	<u>89,850</u>	<u>60,009</u>	<u>149,859</u>	<u>217,395</u>
<i>Total 2024</i>	<u>155,150</u>	<u>62,245</u>	<u>217,395</u>	

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

5. Income from charitable activities

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Subscriptions	830	830	875
	<hr/>	<hr/>	<hr/>
<i>Total 2024</i>	<hr/> 875 <hr/>	<hr/> 875 <hr/>	

6. Income from other trading activities

Income from fundraising events

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Fundraising events	5,986	16,042	22,028	21,738
	<hr/>	<hr/>	<hr/>	<hr/>
<i>Total 2024</i>	<hr/> 6,248 <hr/>	<hr/> 15,490 <hr/>	<hr/> 21,738 <hr/>	

7. Investment income

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Investment income	1,235	1,235	1,120
	<hr/>	<hr/>	<hr/>
<i>Total 2024</i>	<hr/> 1,120 <hr/>	<hr/> 1,120 <hr/>	

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

8. Other incoming resources

	Unrestricted funds 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Other income	-	-	1,149
	<hr/>	<hr/>	<hr/>
<i>Total 2024</i>	<hr/> 1,149 <hr/>	<hr/> 1,149 <hr/>	

9. Analysis of grants

	Grants to Individuals 2025 £	Grants to Institution 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Grants	1,900	24,616	26,516	12,728
	<hr/>	<hr/>	<hr/>	<hr/>
<i>Total 2024</i>	<hr/> 420 <hr/>	<hr/> 12,308 <hr/>	<hr/> 12,728 <hr/>	

In 2025 1 grant was given to institutions (2024: 1) and 8 to individuals (2024: 1).

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

10. Analysis of expenditure by activities

	Activities undertaken directly 2025 £	Grant funding of activities 2025 £	Support costs 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Charitable activities	151,085	26,516	34,610	212,211	197,548
<i>Total 2024</i>	<u>152,079</u>	<u>12,728</u>	<u>32,741</u>	<u>197,548</u>	

Analysis of direct costs

	Charitable activities 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Staff costs	24,533	24,533	24,533
Conference expenses	32,764	32,764	27,449
Walking Course	-	-	9,848
Consultancy	55,505	55,505	52,271
Travel and accommodation expenses	940	940	928
Freelancer consulting costs	37,090	37,090	37,050
Patient and Family meetings	253	253	-
Total 2025	<u>151,085</u>	<u>151,085</u>	<u>152,079</u>
<i>Total 2024</i>	<u>152,079</u>	<u>152,079</u>	

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

10. Analysis of expenditure by activities (continued)

Analysis of support costs

	Charitable activities 2025 £	Total funds 2025 £	<i>Total funds 2024 £</i>
Rent	1,896	1,896	1,842
Office Costs	651	651	308
Online services	1,095	1,095	962
Website and computer costs	8,446	8,446	10,594
Sundry expenses	10	10	425
Subscriptions	566	566	599
Insurance	677	677	706
Printing, post and stationery	4,064	4,064	3,189
Fundraising	320	320	101
Depreciation - office equipment	204	204	216
Amortisation - website development	-	-	-
Staff training	-	-	-
Accountancy & payroll	11,438	11,438	9,602
Independent examiners fee	3,186	3,186	2,963
Staff costs	2,057	2,057	1,234
Total 2025	<u>34,610</u>	<u>34,610</u>	<u>32,741</u>
<i>Total 2024</i>	<u>32,741</u>	<u>32,741</u>	

During the year ended 31 March 2025, the company incurred the following Governance costs:

£14,624 (2024 - £12,590) included in the table above.

11. Independent examiner's remuneration

The independent examiner's remuneration amounts to an independent examiner fee of £3,186 (2024 - £2,963).

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

12. Staff costs

	2025 £	2024 £
Wages and salaries	24,000	24,000
Social security costs	2,057	1,234
Pension costs	533	533
	<u>26,590</u>	<u>25,767</u>

The average number of persons employed by the company during the year was as follows:

	2025 No.	2024 No.
	<u>1</u>	<u>1</u>

The key management personnel of the charity are the Trustees and Chief Executive. Total employee benefits of key management personnel of the charity were £24,533 (2024: £24,533).

No employee received remuneration amounting to more than £60,000 in either year.

13. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year ended 31 March 2025, expenses totalling £362 were reimbursed or paid directly to 1 Trustee (2024 - £NIL to 1 Trustees) to cover expenses incurred relating to travel expense reimbursement for the Hepatic Get Together and Team Meetings.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

14. Intangible assets

	Website development t £
Cost	
At 1 April 2024	23,938
At 31 March 2025	<u>23,938</u>
Amortisation	
At 1 April 2024	23,938
At 31 March 2025	<u>23,938</u>
Net book value	
At 31 March 2025	<u><u>-</u></u>
<i>At 31 March 2024</i>	<u><u>-</u></u>

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

15. Tangible fixed assets

	Office equipment £
Cost or valuation	
At 1 April 2024	7,538
At 31 March 2025	<u>7,538</u>
Depreciation	
At 1 April 2024	6,740
Charge for the year	204
At 31 March 2025	<u>6,944</u>
Net book value	
At 31 March 2025	<u><u>594</u></u>
At 31 March 2024	<u><u>798</u></u>

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

16. Debtors

	2025 £	2024 £
Due within one year		
Other debtors	5,106	2,512
Prepayments and accrued income	1,043	966
	<u>6,149</u>	<u>3,478</u>
	<u><u>6,149</u></u>	<u><u>3,478</u></u>

17. Creditors: Amounts falling due within one year

	2025 £	2024 £
Trade creditors	2,970	-
Other taxation and social security	592	-
Other creditors	1,184	1,933
Accruals and deferred income	5,427	4,927
	<u>10,173</u>	<u>6,860</u>
	<u><u>10,173</u></u>	<u><u>6,860</u></u>

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

18. Statement of funds

Statement of funds - current year

	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2025 £
Unrestricted funds					
General Funds - all funds	43,596	78,116	(67,087)	(18,638)	35,987
	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2025 £
Restricted funds					
Type 2 Pompe	3,941	695	(3,512)	-	1,124
Type 5 Mcardle	4,855	28,772	(23,870)	-	9,757
Type 3 Cori	375	-	-	(375)	-
Type 1 Van Gierke	12,775	-	-	(12,775)	-
Type 6 Hers Fund	602	-	-	(602)	-
Type 0	165	-	-	(165)	-
Better treatments and service access	-	15,633	(22,088)	6,455	-
Help with living well	7	21,183	(26,574)	5,384	-
Support across the community	224	28,683	(35,706)	6,799	-
PHD Project	61,542	-	(24,616)	-	36,926
Hepatic	-	870	(8,758)	13,917	6,029
	84,486	95,836	(145,124)	18,638	53,836
	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2025 £
Total of funds	128,082	173,952	(212,211)	-	89,823

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

18. Statement of funds (continued)

Statement of funds - prior year

	<i>Balance at 1 April 2023 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Transfers in/out £</i>	<i>Balance at 31 March 2024 £</i>
Unrestricted funds					
General Funds - all funds	24,159	80,879	(61,069)	(373)	43,596
Restricted funds					
Type 2 Pompe	7,294	-	(3,353)	-	3,941
Type 5 Mcardle	8,528	28,658	(32,331)	-	4,855
Type 3 Cori	3,309	-	(2,934)	-	375
Type 1 Van Gierke	17,532	-	(4,757)	-	12,775
Type 6 Hers Fund	602	-	-	-	602
Conferences	21,331	1,190	(22,631)	110	-
Type 0	165	-	-	-	165
Better treatments and service access	-	15,733	(15,996)	263	-
Help with living well	-	23,833	(23,826)	-	7
Support across the community	433	18,134	(18,343)	-	224
PHD Project	-	73,850	(12,308)	-	61,542
	59,194	161,398	(136,479)	373	84,486
Total of funds	83,353	242,277	(197,548)	-	128,082

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

19. Summary of funds

Summary of funds - current year

	Balance at 1 April 2024 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 March 2025 £
General funds	43,596	78,116	(67,087)	(18,638)	35,987
Restricted funds	84,486	95,836	(145,124)	18,638	53,836
	<u>128,082</u>	<u>173,952</u>	<u>(212,211)</u>	<u>-</u>	<u>89,823</u>

Summary of funds - prior year

	<i>Balance at 1 April 2023 £</i>	<i>Income £</i>	<i>Expenditure £</i>	<i>Transfers in/out £</i>	<i>Balance at 31 March 2024 £</i>
General funds	24,159	80,879	(61,069)	(373)	43,596
Restricted funds	59,194	161,398	(136,479)	373	84,486
	<u>83,353</u>	<u>242,277</u>	<u>(197,548)</u>	<u>-</u>	<u>128,082</u>

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

19. Summary of funds (continued)

Restricted Funds

Type 2 Pompe's

Supporting GSD Type 2, Pompe.

Type 5 McArdles

Supporting GSD Type 5, McArdle.

Type 3 Cori

Supporting GSD Type 3, Cori.

Type 1 Von Gierke

Supporting GSD Type 1, Von Gierke.

Type 6 Hers Fund

Supporting GSD Type 6, Hers.

Hardship Fund

Supporting patients and families suffering hardship.

Conferences

Supporting AGSD-UK Annual conference.

Medical Advisory Board

Supporting meetings of AGSD-UK Medical Advisors.

Specialist Care Advisor

Supporting the provision of a Pompe patient support worker.

Type 0

Supporting GSD Type 0.

Patient Education and Empowerment

Supporting patients and families by providing family days.

Better treatments and service access

Supporting activities to promote better treatments and service access through research engagement and work with professionals and partners.

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

19. Summary of funds (continued)

Help with living well

Supporting activities to enable people affected to live well with GSDs, including information, educational programmes and therapeutic activities.

Support across the community

Supporting activities to ensure support is available across the GSD community.

PHD Projects

Grant contribution to PhD studentship 1
Eating, physical activity and mental health.

Grant contribution to PhD studentship 2
Investigating digital biomarkers to support safe physical activity.

Hepatic

Supporting people affected by hepatic GSDs

Transfers between funds

A transfer of £6,455 was made during the year from the general fund to the Better Treatments and Service Access fund, of £5,384 to the Help With Living Well fund, £6,799 to the Support Across the Community fund to cover the deficits at the year end.

Transfers of £375 from Type 3 Cori fund, £12,775 from the Type 1 Van Gierke fund, £602 from the Type 6 Hers fund and £165 from the Type 0 fund were made to the Hepatic fund. The hepatic funds have been amalgamated to recognise that funds allocated to GSD1 were intended for use across hepatic GSDs.

20. Analysis of net assets between funds

Analysis of net assets between funds - current year

	Restricted funds 2025 £	Unrestricted funds 2025 £	Total funds 2025 £
Tangible fixed assets	-	594	594
Current assets	53,917	45,485	99,402
Creditors due within one year	(81)	(10,092)	(10,173)
Total	53,836	35,987	89,823

ASSOCIATION FOR GLYCOGEN STORAGE DISEASE (UK) LIMITED
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

20. Analysis of net assets between funds (continued)

Analysis of net assets between funds - prior year

	<i>Restricted funds 2024 £</i>	<i>Unrestricted funds 2024 £</i>	<i>Total funds 2024 £</i>
Tangible fixed assets	-	798	798
Current assets	86,020	48,124	134,144
Creditors due within one year	(1,534)	(5,326)	(6,860)
Total	84,486	43,596	128,082

21. Pension commitments

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in independently administered funds. The pension cost shown in note 11 represents the contributions payable by the Charity to these funds. Included in other creditors is a balance of £81 (2024 - £104) which relates to the pension fund.

22. Related party transactions

There were no related party transactions in the year ended 31 March 2025.